« Back
Home /
Naquotinib (mesylate)

Naquotinib (mesylate)

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer
Type	Inhibitors
Specific against	other
Amount	1mg
Quantity options	100 mg 10mM*1 mL 10 mg 1mg 25 mg 50 mg 5 mg
Item no.	HY-19803-1mg
Targets	EGFR
CASRN	1448237-05-5
eClass 6.1	30220300
eClass 9.0	32160605
Available
Alias	ASP8273 (mesylate)
Purity	98.02
Product Description	Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	658.81
Clinical_Information	Phase 3
Manufacturers Research Area	Cancer
Solubility	DMSO : 12.5 mg/mL (ultrasonic; warming)
Manufacturers Target	EGFR
Isoform	EGFR/ErbB1/HER1
Pathway	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19803-1mg-safety-datasheet.pdf